Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese medical device company, has announced that its Vewatch vena cava filter has received approval from the National Medical Products Administration (NMPA) for the prevention of pulmonary embolism caused by thrombus detachment in the inferior vena cava system.
This product marks MicroPort Endovascular’s first entry into the field of peripheral vein devices aimed at preventing the occurrence or recurrence of pulmonary embolism. The Vewatch filter features a double-layer umbrella structure design that effectively intercepts detached deep vein thrombosis and offers an extended recovery time window. Its unique femoral centered release design enhances the neutrality of the filter within the blood vessel post-implantation, reducing the risk of filter tilting and improving the success rate of thrombus interception and subsequent filter recovery.- Flcube.com
